NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free SANA Stock Alerts $8.19 +0.10 (+1.24%) (As of 12:10 PM ET) Add Compare Share Share Today's Range$8.04▼$8.3350-Day Range$7.22▼$11.2752-Week Range$2.74▼$12.00Volume292,021 shsAverage Volume3.04 million shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sana Biotechnology alerts: Email Address Sana Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside42.5% Upside$11.67 Price TargetShort InterestBearish22.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 4 Articles This WeekInsider TradingAcquiring Shares$10 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.02) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector513th out of 909 stocksBiological Products, Except Diagnostic Industry80th out of 156 stocks 3.4 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSana Biotechnology has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.16% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 1.1 News and Social Media Coverage News SentimentSana Biotechnology has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sana Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,999,996.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.02) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Sana Biotechnology Stock (NASDAQ:SANA)Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Read More SANA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SANA Stock News HeadlinesApril 22, 2024 | bizjournals.comSana Biotechnology R&D leader Douglas Williams steps downApril 20, 2024 | investing.comSana Biotechnology EVP Williams resigns from R&D postApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 20, 2024 | americanbankingnews.comContrasting PharmaCyte Biotech (NASDAQ:PMCB) and Sana Biotechnology (NASDAQ:SANA)March 17, 2024 | seekingalpha.comSana Biotechnology: Now In Overbought TerritoryMarch 16, 2024 | finance.yahoo.comSANA Apr 2024 15.000 callMarch 14, 2024 | finance.yahoo.comJ&J, Novo support Asgard’s push to make ‘in vivo’ cell therapiesMarch 11, 2024 | finance.yahoo.comDirector Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)April 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...March 7, 2024 | finance.yahoo.comBaillie Gifford Bolsters Stake in Sana Biotechnology IncMarch 1, 2024 | markets.businessinsider.comSana Biotechnology: Buy Rating Affirmed Amid Anticipation of Clinical Breakthroughs and Hypoimmune Platform ValidationMarch 1, 2024 | markets.businessinsider.comSana Biotechnology: Promising Clinical Prospects and Buy Rating Justified by Upcoming Data ReadoutsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA) and Sana Biotechnology (SANA)February 29, 2024 | globenewswire.comSana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesFebruary 28, 2024 | globenewswire.comSana Biotechnology to Present at the Cowen 44th Annual Health Care ConferenceFebruary 19, 2024 | finance.yahoo.comInstitutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gainFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 13, 2024 | finance.yahoo.comSana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHPFebruary 12, 2024 | finance.yahoo.comSana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesFebruary 9, 2024 | msn.comSana Biotechnology Announces Pricing of Upcoming OfferingFebruary 9, 2024 | msn.comSana Biotechnology’s Major Public Offering AgreementFebruary 8, 2024 | bizjournals.comSana Biotechnology raising $165M through public offeringFebruary 8, 2024 | msn.comSana Biotechnology Previews Preliminary Financials and Trial ProgressFebruary 8, 2024 | msn.comSana Biotechnology down 5%, prices $165M offeringFebruary 8, 2024 | markets.businessinsider.comSana Biotechnology Prices Upsized Public Offering Of $165 Mln Of SharesFebruary 8, 2024 | finance.yahoo.comSana Biotechnology Announces Pricing of Upsized Public OfferingFebruary 7, 2024 | marketwatch.comSana Biotechnology Shares Fall After Public Offering NewsSee More Headlines Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/24/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees328Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+44.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-283,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.36% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book5.54Miscellaneous Outstanding Shares220,450,000Free Float143,512,000Market Cap$1.78 billion OptionableOptionable Beta1.61 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Steven D. Harr M.D. (Age 54)President, CEO & Director Comp: $1.04MMr. Bernard J. Cassidy J.D. (Age 69)Executive VP, General Counsel & Corporate Secretary Comp: $491.39kMr. Nathan Hardy M.B.A. (Age 48)Executive VP & CFO Comp: $683.49kDr. Edward Rebar Ph.D. (Age 56)Senior VP & CTO Ms. Robin Andrulevich (Age 58)Executive VP & Chief People Officer Mr. Paul Brunetta M.D.Senior VP and Head of Clinical & Translational ScienceMr. Christian Hordo M.B.A. (Age 41)Executive VP & Chief Business Officer Comp: $485.03kDr. Sonja Schrepfer M.D. (Age 49)Ph.D., Senior VP & Head of Hypoimmune Platform Dr. Terry Fry M.D. (Age 57)Senior VP & Head of T Cell Therapeutics Dr. Steven A. Goldman M.D. (Age 66)Ph.D., Senior VP & Head of CNS Therapy More ExecutivesKey CompetitorsRecursion PharmaceuticalsNASDAQ:RXRXFusion PharmaceuticalsNASDAQ:FUSNTwist BioscienceNASDAQ:TWSTGinkgo BioworksNYSE:DNABeam TherapeuticsNASDAQ:BEAMView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCSold 64,393 shares on 4/5/2024Ownership: 0.032%PFM Health Sciences LPBought 639,198 shares on 2/15/2024Ownership: 0.955%HarbourVest Partners LLCSold 20,000 shares on 2/15/2024Ownership: 0.060%Rafferty Asset Management LLCBought 112,732 shares on 2/13/2024Ownership: 0.222%Corient Private Wealth LLCBought 130,500 shares on 2/9/2024Ownership: 0.210%View All Insider TransactionsView All Institutional Transactions SANA Stock Analysis - Frequently Asked Questions Should I buy or sell Sana Biotechnology stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SANA shares. View SANA analyst ratings or view top-rated stocks. What is Sana Biotechnology's stock price target for 2024? 4 brokers have issued 1-year price objectives for Sana Biotechnology's shares. Their SANA share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $11.67 in the next year. This suggests a possible upside of 42.5% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts. How have SANA shares performed in 2024? Sana Biotechnology's stock was trading at $4.08 on January 1st, 2024. Since then, SANA shares have increased by 100.7% and is now trading at $8.19. View the best growth stocks for 2024 here. When is Sana Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SANA earnings forecast. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) posted its earnings results on Thursday, February, 29th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. During the same quarter in the previous year, the firm earned ($0.40) EPS. What ETFs hold Sana Biotechnology's stock? ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Global X Genomics & Biotechnology ETF (GNOM). When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.03%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang, Robert Nelsen and Ventures Fund V Gener Flagship. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SANA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
